Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
23.29
+0.37 (1.61%)
Oct 8, 2025, 9:54 AM EDT - Market open
Castle Biosciences Revenue
Castle Biosciences had revenue of $86.19M in the quarter ending June 30, 2025, a decrease of -0.94%. This brings the company's revenue in the last twelve months to $346.27M, up 20.40% year-over-year. In the year 2024, Castle Biosciences had annual revenue of $332.07M with 51.09% growth.
Revenue (ttm)
$346.27M
Revenue Growth
+20.40%
P/S Ratio
1.88
Revenue / Employee
$455,018
Employees
761
Market Cap
675.60M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 332.07M | 112.28M | 51.09% |
Dec 31, 2023 | 219.79M | 82.75M | 60.38% |
Dec 31, 2022 | 137.04M | 42.95M | 45.65% |
Dec 31, 2021 | 94.09M | 31.44M | 50.18% |
Dec 31, 2020 | 62.65M | 10.78M | 20.79% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CSTL News
- 6 days ago - Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine - GlobeNewsWire
- 15 days ago - Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award - GlobeNewsWire
- 21 days ago - Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025 - GlobeNewsWire
- 4 weeks ago - New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions - GlobeNewsWire
- 5 weeks ago - Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential - Seeking Alpha
- 6 weeks ago - New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma - GlobeNewsWire
- 6 weeks ago - Castle Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript - Seeking Alpha